ECRAID-Prime: European Clinical Research Alliance on Infectious Diseases - PRIMary care adaptive platform trial for pandemics and Epidemics
Trial Aim
ECRAID-Prime is an intervention study that is investigating medical products to treat respiratory infections in adult patients across Europe.
Participant Information Documents
ECRAID-Prime is an intervention study that is investigating medical products to treat respiratory infections in adult patients across Europe.
Contact Details
ecraid-prime@phc.ox.ac.uk
Funding Details
European Union’s HORIZON 2021 – 2027 Research and Innovation Programme
Sponsored by University Medical Center Utrecht (UMCU) (Netherlands)
Background and Study Aims
Respiratory infections can be caused by SARS-CoV-2 (the virus that causes COVID-19), influenza, and other respiratory viruses and bacteria.
The ECRAID-Prime study aims to find treatments for respiratory infections that can help:
- Speed up recovery
- Reduce the severity of symptoms
- Reduce hospital admissions
- Prevent the spread of viruses to your family or household members
Who can participate?
To be eligible to participate, you will need to be 18 years of age or older and experiencing symptoms of a respiratory infection such as runny nose, sore throat, cough, tiredness, headache and/or high temperature/fever with recent onset.
What are the possible risks and benefits of participating?
Risks: The medical products may cause some side effects. There may be also be some discomfort from (self) taking of the combined throat/nose swabs.
Benefits: Participants may benefit from the effects of any medical product they could be given. However, we do not yet confidently know how well any of the study products work. Nevertheless, even though taking part may not benefit the participants personally, their participation will help researchers and doctors learn about the safety and any benefits of the medical products we are testing. Thereby, the treatment of other patients with respiratory infections might be improved.
What does the study involve?
Participating is easy. Your GP takes a combined throat/nose swab, which we will use to find out what is causing your respiratory infection.
If you participate, you will be randomised (allocated purely by chance) to receive:
- Medical product in addition to usual care
- Control product in addition to usual care
- Usual care alone
Additionally, you will receive instructions on how and for how long to use to medical product (if you are randomised to receive a medical product), combined throat/nose swabs to self-swab at day 4, 7 and 14, and a diary.
If you participate, you will be asked:
- To take the medical product according to instructions (if you are randomised to receive a medical product
- To complete the diary at the end of each day for 28 days
- To take a combined throat/nose self-swab at day 4, 7 and 14, and store the swabs in your freezer
- To answer questions by phone or online after 3 and 6 months
Trial Team
-
-
-
Ellie Newbury
Assistant Trial Manager
-
Emma Harper
Trial Manager
-
Yenabeb Ayalew
Clinical Trial Administrator
-
-
Fiona Mowbray
Qualitative Researcher
OXFORD CO-INVESTIGATORS
EXTERNAL CO-INVESTIGATORS
Related Publications
Patients’ and clinicians’ perspectives on the primary care consultations for acute respiratory infections during the first wave of the COVID-19 pandemic: an eight-country qualitative study in Europe
Marta Wanat, Melanie Eugenie Hoste, Nina Helene Gobat, Marilena Anastasaki, Femke Böhmer, Slawomir Chlabicz, Annelies Colliers, Karen Farrell, Sophie Hollerbach, Maria-Nefeli Karkana, John Kinsman, Christos Lionis, Ludmila Marcinowicz, Katrin Reinhardt, Ingmarie Skoglund, Pär-Daniel Sundvall, Akke Vellinga, Herman Goossens, Christopher C Butler, Alike van der Velden, Sibyl Anthierens, Sarah Tonkin-Crine